Related Experiment Video
Updated: Aug 13, 2026
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Outcomes of weight-based heparin dosing based on literature guidelines and institution individualization
Insights
Weight-based dosing of unfractionated heparin (UFH) frequently fails to achieve therapeutic levels. This study suggests that using patient weight alone may be insufficient for optimizing UFH therapy.
Area of Science:
- Pharmacology
- Clinical Medicine
- Thrombosis Research
Background:
- Unfractionated heparin (UFH) is a critical anticoagulant.
- Optimal dosing is essential for efficacy and safety.
- Current guidelines often rely on weight-based protocols.
Purpose of the Study:
- To evaluate the effectiveness of standard weight-based guidelines for dosing UFH.
- To determine if current weight-based protocols achieve therapeutic anticoagulation.
- To assess the adequacy of weight-based UFH dosing in a clinical setting.
Main Methods:
- Prospective, 6-month study at a university hospital.
- Two groups received different weight-based UFH dosing regimens (WBHD1 and WBHD2).
- Activated partial thromboplastin times (aPTTs) were monitored at 24 and 48 hours.
Main Results:
- Low percentages of patients achieved therapeutic aPTTs within 48 hours in both dosing groups (WBHD1: 54.3%, WBHD2: 51.4%).
- No significant difference in therapeutic aPTT achievement between the two weight-based dosing strategies.
- Bleeding episodes and thromboembolic events were also monitored.
Conclusions:
- Published weight-based guidelines for UFH dosing result in suboptimal therapeutic anticoagulation.
- Relying solely on patient weight may not be adequate for optimizing UFH therapy.
- Further research into alternative or adjusted dosing strategies is warranted.
Study Objective:
To determine whether unfractionated heparin is optimally dosed using published weight-based guidelines.
Design:
Six-month, prospective study.
Setting:
University hospital.
Patients:
Ninety-six patients in the weight-based unfractionated heparin-dosing group 1 (WBHD1; 37 men; mean age 66.9 +/- 15.1 years; mean weight 80.1 +/- 20.6 kg) and 68 patients in the WBHD2 (25 men; mean age 68.2 +/- 15.6 years; mean weight 82.0 +/- 19.6 kg).
Interventions:
The WBHD1 received a 100-U/kg intravenous bolus followed by an 18-U/kg/hour continuous intravenous infusion. After 3 months, the protocol was modified, and the WBHD2 received a 90-U/kg bolus followed by a 16-U/kg/hour continuous infusion for 3 months.
Measurements And Main Results:
Activated partial thromboplastin times (aPTTs), frequency of bleeding episodes that required blood transfusions, and the number of recurrent thromboembolic events were collected from both groups after 3 months on the study. In the WBHD1, 24 hours after starting heparin, 38.5% of patients had therapeutic aPTTs, and at 48 hours, 54.3% were therapeutic. In the WBHD2, 42.6% and 51.4% of patients had therapeutic aPTTs at 24 and 48 hours, respectively. There was no statistical difference between the WBHD1 and WBHD2 in the percentage of patients with therapeutic aPTTs.
Conclusions:
Weight-based heparin dosing resulted in low percentages of patients with therapeutic aPTTs. The use of weight alone to dose heparin may not be adequate to optimize therapy.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:28Dosage Regimens: Designs and Approaches
01:24Dosage Regimen: Individualization
01:23Dosage Regimen Designs: Nomograms and Tabulations
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
01:29Venous Thrombosis III: Interprofessional Care